Benzodiazepines and risk of death: Results from two large cohort studies in France and UK

European Neuropsychopharmacology

Volumn 25, Issue 10, 2015, Pages 1566-1577

  Palmaro, Aurore ^a,b   Dupouy, Julie ^a   Lapeyre Mestre, Maryse ^a,b  

^a Faculté de Médecine Centre Hospitalo universitaire   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Anti anxiety agents; Benzodiazepines; Cohort studies; Hypnotics and sedatives; Mortality

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; DIAZEPAM; SEDATIVE AGENT; TEMAZEPAM; ZOLPIDEM; ZOPICLONE; ANXIOLYTIC AGENT; HYPNOTIC SEDATIVE AGENT;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CAUSE OF DEATH; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EXPOSURE; DRUG FATALITY; FEMALE; FOLLOW UP; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; SEX DIFFERENCE; SHORT TERM SURVIVAL; SOCIAL STATUS; TREATMENT DURATION; UNITED KINGDOM; ADOLESCENT; DRUG DATABASE; EPIDEMIOLOGY; GREAT BRITAIN; MIDDLE AGED; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ANXIETY AGENTS; BENZODIAZEPINES; COHORT STUDIES; DATABASES, PHARMACEUTICAL; FEMALE; FRANCE; GREAT BRITAIN; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; MORTALITY; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84943356381     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.07.006     Document Type: Article

References (37)

1. Agence française de sécurité sanitaire des produits de santé, 2012. État des lieux de la consommation des benzodiazépines en France Afssaps - Rapport d'expertise. (accessed 25.05.15). http://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Etat-des-lieux-en-2013-de-la-consommation-des-benzodiazepines-en-France-Point-d-Information.
2. Amarasuriya U.K., Myles P.R., et al. Long-term benzodiazepine use and mortality: are we doing the right studies?. Curr. Drug Saf. 2012, 7(5):367-371.
3. Blin P., Lassalle R., et al. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia 2012, 55(3):644-653.
4. Charlson F., Degenhardt L., et al. A systematic review of research examining benzodiazepine-related mortality. Pharmacoepidemiol. Drug Saf. 2009, 18(2):93-103.
5. Charlton R.A., Cunnington M.C., et al. Data resources for investigating drug exposure during pregnancy and associated outcomes: the General Practice Research Database (GPRD) as an alternative to pregnancy registries. Drug Saf. 2008, 31(1):39-51.
6. Coupland C., Dhiman P., et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011, 343:d4551.
7. Delaney J.A., Moodie E.E., et al. Validating the effects of drug treatment on blood pressure in the General Practice Research Database. Pharmacoepidemiol. Drug Saf. 2008, 17(6):535-545.
8. Devine S., West S.L., et al. Validation of neural tube defects in the full featured-general practice research database. Pharmacoepidemiol. Drug Saf. 2008, 17(5):434-444.
9. Dupouy J., Fournier J.P., et al. Baclofen for alcohol dependence in France: incidence of treated patients and prescription patterns-a cohort study. Eur. Neuropsychopharmacol. 2013, 24(2):192-199.
10. Gallini A., Andrieu S., et al. Trends in use of antipsychotics in elderly patients with dementia: impact of national safety warnings. Eur. Neuropsychopharmacol. 2013, 24(1):95-104.
11. Garcia Rodriguez L.A., Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br. J. Clin Pharmacol. 1998, 45(5):419-425.
12. Ghosn W., Kassie D., et al. Spatial interactions between urban areas and cause-specific mortality differentials in France. Health Place 2013, 24:234-241.
13. Hausken A.M., Skurtveit S., et al. Use of anxiolytic or hypnotic drugs and total mortality in a general middle-aged population. Pharmacoepidemiol. Drug Saf. 2007, 16(8):913-918.
14. Horsfall L., Walters K., et al. Identifying periods of acceptable computer usage in primary care research databases. Pharmacoepidemiol. Drug Saf. 2012, 22(1):64-69.
15. Huybrechts K.F., Rothman K.J., et al. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ 2011, 183(7):E411-E419.
16. Jaussent I., Ancelin M.-L., et al. Hypnotics and mortality in an elderly general population: a 12-year prospective study. BMC Med. 2013, 11(1):212.
17. Johnson E.S., Bartman B.A., et al. The incident user design in comparative effectiveness research. Pharmacoepidemiol. Drug Saf. 2013, 22(1):1-6.
18. Khan N.F., Perera R., et al. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam. Pract. 2010, 11:1.
19. Kripke D.F., Langer R.D., et al. Hypnotics' association with mortality or cancer: a matched cohort study. BMJ Open 2012, 2(1):e000850.
20. Maguire A., Blak B.T., et al. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol. Drug Saf. 2009, 18(1):76-83.
21. McCowan C., Kidd B., et al. Factors associated with mortality in Scottish patients receiving methadone in primary care: retrospective cohort study. BMJ 2009, 338:b2225.
22. Obiora E., Hubbard R., et al. The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort. Thorax 2013, 68(2):163-170.
23. Office for National Statistics, 2007. General Household Survey, 2007 Report. (accessed 25.05.15). http://www.ons.gov.uk/ons/rel/ghs/general-household-survey/2007-report/index.html.
24. Payne R.A., Abel G.A. UK indices of multiple deprivation - a way to make comparisons across constituent countries easier. Health Stat. Q. 2012, 53:22-37.
25. Quan H., Sundararajan V., et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med. Care 2005, 43(11):1130-1139.
26. Rey G., Fouillet A., et al. Heat exposure and socio-economic vulnerability as synergistic factors in heat-wave-related mortality. Eur. J. Epidemiol. 2009, 24(9):495-502.
27. Rey G., Jougla E., et al. Ecological association between a deprivation index and mortality in France over the period 1997-2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health 2009, 9:33.
28. Schneeweiss S., Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J. Clin. Epidemiol. 2005, 58(4):323-337.
29. Smoller J.W., Allison M., et al. Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women[U+05F3]s Health Initiative study. Arch. Intern. Med. 2009, 169(22):2128-2139.
30. Tiihonen J., Suokas J.T., et al. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch. Gen. Psychiatry 2012, 69(5):476-483.
31. Tuppin P., de Roquefeuil L., et al. French national health insurance information system and the permanent beneficiaries sample. Rev. Epidemiol. Sante Publique 2010, 58(4):286-290.
32. Vozoris N.T., Fischer H.D., et al. Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD. Eur. Respir. J. 2014, 44(2):332-340.
33. Walley T., Mantgani A. The UK General Practice Research Database. Lancet 1997, 350:1097-1099.
34. Weich S., Pearce H.L., et al. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ 2014, 348:1996.
35. WHO Collaborating Centre for Drug Statistics Methodology, ATC classification and DDD assignment. 16th edition. WHO Collaborating Centre for Drug Statistics Methodology. Norwegian Institute of Public Health. 2015; (accessed 25.05.15). http://www.whocc.no/atc_ddd_index/.
36. Winkelmayer W.C., Mehta J., et al. Benzodiazepine use and mortality of incident dialysis patients in the United States. Kidney Int. 2007, 72(11):1388-1393.
37. Wood L., Martinez C. The general practice research database: role in pharmacovigilance. Drug Saf. 2004, 27(12):871-881.